Trial Profile
A Randomized, Open-label Phase 3 Study of Carfilzomib, Melphalan, and Prednisone versus Bortezomib, Melphalan, and Prednisone in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Feb 2022
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Carfilzomib (Primary) ; Dexamethasone; Melphalan; Prednisone
- Indications Myeloma
- Focus Therapeutic Use
- Sponsors Ono Pharmaceutical
- 13 Nov 2017 Status changed from active, no longer recruiting to completed.
- 06 Jun 2016 New trial record